coplug
    Back to PCN explorer
    PCN reports · Core20PLUS5

    South Warrington PCN, Warrington (LAD) · Health Inequalities Profile

    PCN U31313 · NHS Cheshire and Merseyside Integrated Care Board · 5 GP practices

    Read the report

    This report is generated by Coplug's Healthcare Agent. Log in to ask further questions of it, add the spatial context, or create new enquiries to better understand and improve your Neighbourhood's Health

    01 / 15

    Board summary

    Key figures

    53,994

    Registered population

    58.3% aged 18–64

    22.5%

    Aged 65+

    ICB 19.0% · England 17.9%

    5.9%

    Ethnic minority (non-White)

    2.8% Asian · England 9.6%

    3.4%

    In IMD quintile 1

    ICB 31.9% · England 21.0%

    ~2,375

    Core20 residents (est.)

    Resident basis; registered basis ~1,997 · see page 3

    8,414

    Hypertension register

    +6.34% in 3 yrs · England +5.60%

    351

    SMI register

    15.8% of Warrington (LAD)'s

    661

    COPD register

    Reviews +5.06% in 3 yrs

    Forecast to 2030

    9,739

    Hypertension patients, 2030

    +1,325 on today

    57.9%

    QRISK ≥20% on statins, 2030

    +1.86pp over 3 yrs

    5.4%

    Cancer prevalence, 2030

    England 4.5%

    Three things the board should see

    51.0%
    Asthma annual review coverage trails England.

    Coverage fell 8.9% over 2023 to 2025 (England +4.4%), leaving an estimated 1,625 patients unreviewed, which may reflect recall gaps.

    54.0%
    High-risk lipid therapy below England benchmark.

    Patients with QRISK ≥ 20% on lipid-lowering therapy trail Warrington (LAD) (61.6%) and England (63.6%), which could reflect recall or prescribing gaps.

    +16.9%
    Hypertension control improved faster than England.

    Treatment to target rose +16.9% over 2023 to 2025 (England +3.6%), though current achievement of 64.0% remains below England's 70.3%.

    Sources & context

    PCN and practice-level primary care data; ICB and provider context on page 8

    Powered by Coplug · Page 1 of 15
    02 / 15

    Population, age and ethnicity

    Aged 65+ patients represent 22.5% of the list, exceeding England's 17.9% benchmark

    South Warrington PCN has 53,994 registered patients. The population is older than comparators: 22.5% (12,134 patients) are aged 65+, compared to Warrington LAD (17.5%), the ICB (19.0%), and England (17.9%), while 58.3% are aged 18-64 and 19.2% aged 0-17. Census resident data records 94.1% White ethnicity, compared to Warrington LAD (93.5%), the ICB (93.0%), and England (81.1%), with a 5.9% ethnic minority share. Projected list growth to 2030 is 1.4% under an unverified methodology. Age figures reflect registered patients; ethnicity reflects Census residents.

    Age profile

    0–1719.2%
    18–6458.3%
    65+22.5%

    65+: ICB 19.0%, England 17.9%

    Ethnicity

    White94.1%
    Asian2.8%
    Mixed1.7%
    Other0.8%
    Black0.6%

    Older people · falls rows are Warrington (LAD) local-authority (LA) data, not PCN

    MeasureLocalNorth WestEnglandPeriod
    Falls admissions, 65+, per 100,000 (Warrington LA)1,7372,0711,9582024/25
    Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN)76.9%82.9%81.9%2024/25
    Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN)56.7%56.6%57.4%2024/25
    Falls admissions, 65 to 79, per 100,000 (Warrington LA)9051,0219552024/25
    Falls deaths, all ages, per 100,000 (Warrington LA)12.118.214.82022‑24
    Sources & context

    Census 2021; Fingertips falls and diabetes. Falls are local-authority data. Ethnic minority = 100% minus White

    Powered by Coplug · Page 2 of 15
    03 / 15

    Deprivation and Core20

    PCN Core20 deprivation averages 3.4% but reaches 23.8% at Latchford Medical Centre

    South Warrington PCN averages IMD decile 8.3 (England 5.5) with 3.4% of registered patients in the Core20 cohort, below Warrington (16.9%), England (21.0%), and the ICB (31.9%). Weighted practice share is 3.7% (a 0.27 pp discrepancy against the PCN rate). Deprivation is concentrated at Latchford Medical Centre, with a 23.8% share (an estimated 1,997 patients), while Brookfield Surgery, Stockton Heath Med.centre, The Lakeside Surgery, and Stretton Medical Centre each record 0.0%. Targeted inequalities resources should focus on Latchford Medical Centre to address the PCN's concentrated Core20 cohort.

    % of patients in IMD quintile 1, by practice

    Dashed line: England 21.0% · right column: Core20 patients, registered basis

    Latchford23.8% · 1,997 patients
    Brookfield0.0% · 0 patients
    Stockton Heath0.0% · 0 patients
    Lakeside0.0% · 0 patients
    Stretton0.0% · 0 patients
    Sources & context

    Deprivation: Index of Multiple Deprivation, applied to registered patients

    Powered by Coplug · Page 3 of 15
    04 / 15

    PLUS groups and inclusion health

    PLUS groups and inclusion health

    351

    SMI register

    0.65% recorded prevalence

    218

    Learning disability register

    0.40% recorded prevalence

    23

    Care homes, 956 beds

    In the PCN catchment

    9.4%

    Provide unpaid care

    Warrington (LAD), Census 2021

    Learning disability prevalence is 0.4% (218 patients) and severe mental illness is 0.7% (351 patients), below Warrington LAD (0.5% and 1.0%) and England (0.6% and 1.0%). Catchment infrastructure includes 23 care homes with 956 beds, though resident registrations are unconfirmed; Warrington borough records 9 rough sleepers (autumn 2025). Lower recorded prevalence may reflect coding practice or case-finding variation; practice register audits would be required to verify clinical case detection.

    Severe mental illness: physical health checks

    For SMI physical checks, 87.0% had blood pressure recorded (England 83.4%) and 85.8% had BMI recorded (England 82.1%). Smoking cessation support was 90.3%, below England (94.2%), Warrington (93.7%), and the ICB (95.2%).

    Sources & context

    QOF registers; Census 2021 carers; care homes and homelessness as supplied. Carers and homelessness are local-authority data

    Powered by Coplug · Page 4 of 15
    05 / 15

    Clinical focus: hypertension and lipids

    Clinical focus: hypertension and lipids

    8,414

    Hypertension register

    +6.34%

    Register growth, 3 yrs

    Warrington (LAD) +6.41% · England +5.60%

    +8.25pp

    BP control, under 80

    ≤140/90 · +7.94pp aged 80+

    +1,325

    More patients by 2030

    Forecast 9,739 (17.54%)

    Hypertension case-finding and control

    Hypertension prevalence is 15.5% (8,414 patients), exceeding England (15.2%) but below Warrington (16.4%) and the ICB (16.8%), giving an unadjusted register gap range of -191 to +445 patients. Patients treated to target reached 64.0% following a +16.9% three-year change (England +3.6%), yet overall control lags England (70.3%), Warrington (68.7%), and the ICB (69.1%). Recent blood pressure recording is 82.0% against 90.0% in England, with control under age 80 at 61.2% (England 67.8%) and aged 80+ at 73.3% (England 81.2%). Hypertension control trails national benchmarks despite recent improvement, which may suggest a role for structured recall for under-controlled patients.

    Lipids and statins

    QRISK ≥ 20% lipid therapy is 54.0% (England 63.6%, Warrington 61.6%, ICB 63.2%). Statin treatment in diabetes without CVD is 66.6% (England 73.2%), with three-year change at -1.3% (England +2.1%). Lower uptake across cohorts compared with England benchmarks could reflect review differences, subject to local audit.

    MeasureItemsCost / itemICBEnglandAnnual spend
    Lipid-modifying, 202682,429£1.50£1.71£1.86£123,644
    Cardiovascular (all), 2025123,936£4.92£4.37£3.33£609,765

    In 2026, the PCN prescribed 82,429 lipid-regulating drug items at £1.50 per item, below Warrington (£1.59), the ICB (£1.71), and England (£1.86), spending £29,674 less than at England's unit cost across £123,644 total spend.

    Sources & context

    QOF hypertension register and BP control indicators; prescribing items and cost as supplied

    Powered by Coplug · Page 5 of 15
    06 / 15

    Clinical focus: respiratory, cancer register and children

    Clinical focus: respiratory, cancer register and children

    Respiratory

    −8.94%

    Asthma reviews, PCN 3-yr % change

    +4.44%

    Asthma reviews, England 3-yr % change

    +0.88%

    Asthma prevalence, PCN 3-yr % change

    Asthma 12-month review coverage fell 8.9% over 2023 to 2025 (England +4.4%) to 51.0% (Warrington 61.4%, ICB 62.3%, England 65.7%), leaving about 1,600 (1,625) of 3,320 patients unreviewed. Second-hand smoke recording in asthma (6-19 yrs) was 63.9% (219 patients), below England (78.8%). COPD prevalence is 1.2% (661 patients) versus 1.8% in Warrington and 1.9% in England (unadjusted gap +323 to +362), while COPD review coverage is 71.6% (England 76.4%). Slower review delivery could reflect recall capacity constraints, unverified locally.

    Cancer register and children's immunisation

    Cancer prevalence is 4.3% (2,312 patients; England 3.8%, Warrington 3.9%), rising +12.4% over 2023 to 2025 (England +9.0%). In childhood immunisations, 12-month 6-in-1 uptake is 95.8%, exceeding the 95.0% target. By age five, MMR dose 2 reaches 92.6% (below target by 2.4 pp; 3.3 pp below dose 1) and the 4-in-1 booster is 90.2% (below target by 4.8 pp), though both exceed England (82.8% and 80.9%).

    Dashed line: 95% national coverage target · solid tick: England

    6-in-1 at 12 months95.8%

    England 91.0%

    6-in-1 complete primary course at 24 months93.5%

    England 92.2%

    MMR dose 1 at 24 months92.6%

    England 88.3%

    MMR dose 2 at age 592.6%

    England 82.8%

    4-in-1 pre-school booster at age 590.2%

    England 80.9%

    Sources & context

    QOF registers and review indicators; childhood immunisation coverage as supplied

    Powered by Coplug · Page 6 of 15
    07 / 15

    Early cancer diagnosis

    Early cancer diagnosis

    55.5%

    Cheshire and Merseyside ICB, stage 1–2

    55.3%

    England, 2022

    75%

    National ambition by 2028

    ~2,640

    Extra early-stage cases a year to reach the ambition

    Stage 1–2 share by cancer type, 2022Cheshire and Merseyside ICBEnglandNo usable stageStaged cancers
    Lung40.4%33.8%11%2,354
    Breast87.1%85.4%11%2,083
    Prostate52.3%53.2%12%2,037
    Bowel44.9%47.0%16%1,674
    Skin cancer86.9%87.8%21%932

    In 2022, 55.5% of cancers with a known stage (7,482 of 13,490) across NHS Cheshire and Merseyside ICB were diagnosed at stage 1 or 2, in line with England (55.3%) but 19.5 pp below the 75.0% national ambition by 2028. Staging coverage was 72.8% (13,490 of 18,522). Reaching the 75.0% ambition requires about 2,640 extra early-stage diagnoses annually, while early-stage share rose 2.6 pp from 52.8% in 2013. Site rates were 22.0% for oesophagus and 87.1% for breast. At PCN level, cervical screening in women aged 25-49 is 74.4% (England 66.8%), with Latchford Medical Centre at 72.4% and Stretton Medical Centre at 72.9%.

    Sources & context

    Stage at diagnosis: National Disease Registration Service

    Powered by Coplug · Page 7 of 15
    08 / 15

    Cancer waits, diagnostics and community services

    Cancer waits, diagnostics and community services

    Cancer waits and diagnostics, Jul 2026 (provisional)

    In provisional July 2026 data, North Cheshire and Mersey NHS Foundation Trust achieved 83.7% on the 62-day cancer standard, 1.3 pp below the 85.0% standard but above Mersey and West Lancashire Teaching Hospitals NHS Trust (78.0%), Manchester University NHS Foundation Trust (72.8%), the ICB (76.2%) and England (71.2%). The trust met the 28-day faster diagnosis (80.2%) and 31-day treatment (98.2%) standards. Diagnostic 6+ week waits were 0.5% for MRI and 2.3% for CT, though echocardiography was 28.0%. These figures reflect provider pathway performance rather than PCN delivery, indicating local secondary diagnostic access.

    Pathways within standard (%)North Cheshire and MerseyMersey and West LancashireManchesterCheshire and Merseyside ICBEngland
    28-day faster diagnosis (75%)80.2172.3980.0677.2579.32
    31-day treatment (96%)98.1795.4692.5495.7192.50
    62-day referral to treatment (85%)83.6777.9672.8576.2371.16
    Diagnostic waits over 6 weeks (%)North Cheshire and MerseyMersey and West LancashireManchesterEngland
    MRI0.5314.0411.6821.40
    CT2.3213.0814.669.92
    Echocardiography28.0434.884.9128.48
    Colonoscopy15.9818.044.5130.83
    Gastroscopy20.2418.1729.3529.02
    All 15 DM01 tests6.3421.178.9823.14
    Community services activityWarrington residentsCheshire and Merseyside ICB
    Care contacts38,550541,280
    Referrals7,32097,150
    Patients with a contact14,830146,240

    Community services (residents of Warrington), Jun 2026 (provisional). In provisional June 2026 Community Services Dataset records, 56% of community contacts for Warrington residents (21,595 of 38,550) were with adults aged 65 and over. These figures reflect borough-wide resident activity rather than PCN delivery, highlighting substantial community service reliance among older adults.

    Sources & context

    Waits and diagnostics: NHS England monthly statistics · ICB and provider data, not PCN

    Powered by Coplug · Page 8 of 15
    09 / 15

    Practice variation and patient experience

    Good practice experience varies by 28.8 pp and phone access spans 33.5 pp

    In 2025/26, overall QOF achievement spanned from 85.4% at Stretton Medical Centre to 100.0% at Latchford Medical Centre and The Lakeside Surgery (England 92.5%). Vaccination and immunisation achievement showed a 32.1 pp spread, from 67.9% at Stockton Heath Med.centre and Stretton Medical Centre to 100.0% at Brookfield Surgery, while all-domain personalised care adjustments reached 20.8% at The Lakeside Surgery.

    GP Patient Survey by practice

    PracticeResponses% in IMD Q1Phone easyRequest led to apptOverall good
    Brookfield Surgery1120.049.7%69.6%83.9%
    Stockton Heath1320.029.0%68.1%73.9%
    Latchford9023.856.5%59.1%64.5%
    Stretton1180.042.8%70.5%62.1%
    Lakeside1210.022.9%54.0%55.1%
    England—~2156.9%71.6%76.7%
    Sources & context

    QOF achievement; GP Patient Survey, practice-level results

    Powered by Coplug · Page 9 of 15
    11 / 15

    What the data can't tell us: gaps and local assets

    What the data can't tell us: gaps and local assets

    Local assets and voluntary sectorPCNWarrington (LAD)AssetPCNWarrington (LAD)
    Care homes (catchment)23 (956 beds)n/aSchools (catchment)64n/a
    Children's centres312Places of worship4889
    Libraries27Primary schools (LA maintained)1428
    Primary academies1131Special schoolsn/a1

    0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.

    Sources & context

    Gaps are modelled estimates against benchmark rates; local assets as supplied

    Powered by Coplug · Page 11 of 15
    12 / 15

    Options for the PCN

    Options for the PCN

    Each option in full

    Option 1

    Structured asthma review recall

    Asthma 12-month review coverage is 51.0% (Warrington 61.4%, ICB 62.3%, England 65.7%) after falling 8.9% over 2023 to 2025 (England +4.4%), leaving 1,625 of 3,320 patients unreviewed. For discussion: practices could run structured annual review recall using a standardised template, checking second-hand smoke status alongside inhaler prescribing. Moderate effort to run.

    Evidence base: the annual asthma review is the process gap between the register and outcomes.

    Policy anchor: Core20PLUS5 chronic respiratory disease priority.

    Option 2

    Hypertension and lipid review recall

    Hypertension prevalence is 15.5% (8,414 patients; Warrington 16.4%, England 15.2%; unadjusted gap -191 to +445). Target control is 64.0% (England 70.3%) and QRISK ≥ 20% lipid therapy is 54.0% (England 63.6%). Moderate effort to run.

    Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.

    Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).

    Option 3

    COPD case-finding and review audit

    COPD QOF prevalence is 1.2% (661 patients) versus 1.8% in Warrington, 1.9% in England, and 2.5% in the ICB (unadjusted gap +323 to +362), with 71.6% review coverage (England 76.4%). Moderate effort to run.

    Evidence base: the copd register is the cohort for spirometry-confirmed diagnosis, annual review and inhaler technique; register size and growth set the workload those interventions must cover.

    Policy anchor: Core20PLUS5 adults: chronic respiratory disease (COPD vaccination and exacerbation reduction); Tobacco and Vapes Bill: smokefree generation.

    Sources & context

    Options are the profile's; evidence base from Coplug's indicator catalogue

    Powered by Coplug · Page 12 of 15
    13 / 15

    Provenance and audit trail

    Provenance and audit trail

    Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.

    RecommendationIndicator(s)Policy anchorData level
    Older adult frailty capacity review (p2)Aged 65+Neighbourhood health framework · NHS vaccination strategyPCN
    Targeted Core20 outreach (p3)Core20 cohort (IMD quintile 1)Core20PLUS5 · 10YHP equity testPCN
    Smoking cessation offer audit (p4)Smoking cessation support and treatment offered to patients with certain conditions (denominator incl. PCAs)MHIS · From Harm to HopePCN
    Hypertension recall and titration protocol (p5)Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs)Core20PLUS5 CVD · CVDPREVENT 2029PCN
    Pre-school booster recall catch-up (p6)MMR dose 2 coverage at age 510YHP sickness to prevention · 95% targetPCN
    Cervical screening recall review (p7)Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs)Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026PCN
    Access and triage workflow review (p9)GPPS good overall experience of the practice10YHP, hospital to communityPractice
    Option 1 · Structured asthma review recall (p12)Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Patients with Asthma (6-19 yrs): Second-hand smoking status recorded in the last 12 months (denominator incl. PCAs)Core20PLUS5 respiratoryPCN
    Option 2 · Hypertension and lipid review recall (p12)Hypertension register · Hypertension: QOF prevalence · Hypertension patients with a recent BP readingCore20PLUS5 CVD · CVDPREVENT 2029PCN
    Option 3 · COPD case-finding and review audit (p12)COPD register · COPD: QOF prevalence · COPD patients with a review in the last 12 monthsCore20PLUS5 approach · Tobacco and Vapes BillPCN
    Sources & context

    Re-run this profile in 12 months to see whether the gaps have narrowed

    Powered by Coplug · Page 13 of 15
    14 / 15

    Data sources

    Data sources

    Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.

    DatasetLevelPeriodUsed for
    Coplug indicator tables: census, deprivation and QOF measuresPCN & Practice2023 to 2025, projected to 2030; 2023 to 2024Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12
    MHCLG, Rough sleeping snapshot in England: autumn 2025Local authorityAutumn 2025Pages 2, 4
    OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713)PCN2024/25Pages 2, 4
    OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002)Local authority2024/25; 2022-24Pages 2, 4
    ONS, Census 2021 TS039: provision of unpaid care (age-standardised)Local authorityCensus 2021Pages 2, 4
    QOF registers, prevalence and care processes (Coplug indicator tables)Practice2023 to 2025, projected to 2030Pages 4, 5, 6, 7, 8, 10
    UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26PCN & PracticeQ1 2025/26Pages 4, 6
    UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026Local authority2025/26 season to 28 Feb 2026Pages 4, 6
    NHS England, Cancer Waiting Times: July 2026 monthly time series with revisionsICB & ProviderJul 2026 (provisional)Pages 7, 8
    NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental dataICB & Local authorityJun 2026 (provisional)Pages 7, 8
    NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026ProviderJul 2026Pages 7, 8
    National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022ICB2022Pages 7, 8
    NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted)PracticeSurvey Jan-Apr 2026Page 9
    NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domainPractice2025/26Page 9
    NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domainPractice2025/26Page 9
    Coplug indicator catalogue — definitions, cohorts, policy anchorsReferenceCurrentEvidence-base lines, page 13
    Sources & context

    Where a period is given as "as supplied", the source file did not state a vintage

    Powered by Coplug · Page 14 of 15
    15 / 15

    Methods, data-quality notes and limitations

    Methods, data-quality notes and limitations

    Methods

    Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.

    Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.

    Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.

    Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.

    Sources & context

    Estimates size the task; they are not confirmed missed patients

    Powered by Coplug · Page 15 of 15